Nine months after filing, a last-minute retreat: ophthalmic therapy startup EIR Biopharma withdraws its US$17 million US IPO plan.

date
14:35 17/11/2026
avatar
GMT Eight
Preclinical biotech company EIR Biopharma has withdrawn its US$17 million IPO plan. It had originally intended to offer 3.8 million shares at US$4 to US$5 per share.
EIR Biopharma is a preclinical-stage biotech company focused on developing in-licensed therapies for ophthalmic diseases. The company withdrew its IPO plan on Monday. It had filed in February 2026 to raise US$17 million by offering 3.8 million shares at a price range of US$4 to US$5 per share. The San Francisco, California-based company was founded in 2022. It had planned to list on the NYSE American but had not yet selected a ticker symbol. Kingswood Capital Markets was slated to be the sole bookrunner for the deal.